Chabiotech Co.,Ltd. (KOSDAQ:085660)

South Korea flag South Korea · Delayed Price · Currency is KRW
21,650
+200 (0.93%)
At close: Feb 27, 2026
85.04%
Market Cap 1.99T
Revenue (ttm) 1.20T
Net Income (ttm) -116.55B
Shares Out 91.92M
EPS (ttm) -1,880.73
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,005,355
Average Volume 1,003,685
Open 22,700
Previous Close 21,450
Day's Range 20,950 - 22,900
52-Week Range 9,260 - 23,950
Beta 0.71
RSI 64.11
Earnings Date Mar 20, 2026

About Chabiotech

Chabiotech Co.,Ltd., a bio company, develops cell and gene therapy related to stem and immune cells in South Korea and internationally. The company provides an umbilical cord blood consignment storage for the treatment of incurable diseases; regenerative medicines, immune cell and stem cell storage services, anti-aging, and solutions for incurable diseases; medical wellness programs, comprising fitness, spa, and scupplements; and customized development, production, clinical, and commercialization services to customers with research and developm... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2002
Employees 278
Stock Exchange KOSDAQ
Ticker Symbol 085660
Full Company Profile

Financial Performance

In 2024, Chabiotech's revenue was 1.05 trillion, an increase of 9.55% compared to the previous year's 953.95 billion. Losses were -8.05 billion, -4.48% less than in 2023.

Financial Statements

News

There is no news available yet.